• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Arobella Medical Announces European CE Mark Approval of Qoustic Wound Therapy System(TM)

Posted on: Wednesday, 18 March 2009, 10:34 CDT

MINNEAPOLIS, March 18 /PRNewswire/ -- Arobella Medical, LLC, announced European CE Mark approval of its Qoustic Wound Therapy System(TM) medical device for ultrasound aided wound care.

The wound therapy system uses a unique, dome-shaped curette tip to apply low-frequency, cavitational ultrasound to wounds. The combination of physical design and ultrasonic energy gently removes dead and diseased tissue cells, kills harmful bacteria and biofilm, and leaves healthy and pre-healing granulation tissue intact. The device is FDA-cleared and is already on sale in the United States.

"The Qoustic Wound Therapy System device offers cutting-edge ultrasound technology several generations ahead of its competitors," said Eliaz Babaev, PhD, president and CEO of Arobella Medical. "We look forward to bringing this device to the international market. Arobella Medical continually strives to be the best in ultrasound, and we have the data to prove it."

About Arobella Medical, LLC

Arobella Medical, LLC is Minneapolis-based medical device company specializing in low-frequency ultrasound in wound management therapies. Arobella Medical, LLC is positioned to become the leader in advanced ultrasound wound care technologies and devices. Arobella Medical, LLC co-founder and CEO Eliaz Babaev has more than 45 years of experience developing, designing and commercializing medical devices that use ultrasound. For more information, go to http://www.arobella.com.

Contact: Glenn Carlson, Business Affairs Manager Arobella Medical, LLC +1-612-288-2826 gcarlson@arobella.com

SOURCE Arobella Medical, LLC

Source: PR Newswire

More News in this Category